Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.06.091 on June 27 2005

Journal of Clinical Oncology, Vol 23, No 22 (August 1), 2005: pp. 4925-4935
© 2005 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coleman, R. E.
Right arrow Articles by Cook, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coleman, R. E.
Right arrow Articles by Cook, R.
Related Articles
Right arrowRelated Editorial
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid

Robert E. Coleman, Pierre Major, Allan Lipton, Janet E. Brown, Ker-Ai Lee, Matthew Smith, Fred Saad, Ming Zheng, Yong Jiang Hei, John Seaman, Richard Cook

From the Weston Park Hospital, Cancer Research Centre, Yorkshire Cancer Research Academic Unit of Clinical Oncology, Sheffield, United Kingdom; McMaster University, Juravinski Cancer Centre, Hamilton, Ontario; University of Waterloo, Department of Statistics and Actuarial Science, Waterloo, Ontario; Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Montréal, Quebec, Canada; Milton S. Hershey Medical Center, Division of Oncology, Hershey, PA; Massachusetts General Hospital, Department of Hematology/Oncology, Boston, MA; Novartis Pharmaceuticals Corp, East Hanover, NJ

Address reprint requests to Robert E. Coleman, MD, Yorkshire Cancer Research Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham Rd, Sheffield S10 2SJ, England, United Kingdom; e-mail: r.e.coleman{at}sheffield.ac.uk

PURPOSE: Three large, randomized trials of patients with bone metastases recently demonstrated that zoledronic acid reduces the risk of skeletal-related events. These trials provide an opportunity for investigating the correlation between bone metabolism and clinical outcome during bisphosphonate therapy.

PATIENTS AND METHODS: Urinary measurements of N-telopeptide (Ntx) and serum bone alkaline phosphatase (BAP) were obtained in 1,824 bisphosphonate-treated patients—1,462 with zoledronic acid (breast, 490; prostate, 411; myeloma, 210; non–small-cell lung, 183; other, 168) and 362 with pamidronate (breast, 254; myeloma, 108). This exploratory cohort analysis grouped patients by baseline and most recent levels of Ntx as low (< 50 nmol/mmol creatinine), moderate (50 to 99 nmol/mmol creatinine), or high (≥ 100 nmol/mmol creatinine), and BAP as low (< 146 U/L) or high (≥ 146 U/L). The relative risks for negative clinical outcomes were estimated for each group using multiple-event and Cox regression models with time-varying covariates.

RESULTS: Patients with high and moderate Ntx levels had 2-fold increases in their risk of skeletal complications and disease progression compared with patients with low Ntx levels (P < .001 for all). High Ntx levels in each solid tumor category were associated with a 4- to 6-fold increased risk of death on study, and moderate Ntx levels a 2- to 4-fold increased risk compared with low Ntx levels (P < .001 for all). Bone alkaline phosphatase also showed some correlation with risk of negative clinical outcomes.

CONCLUSION: The bone resorption marker Ntx provides valuable prognostic information in patients with bone metastases receiving bisphosphonates.

Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • High Bone Turnover Markers Predict Poor Outcome in Patients With Bone Metastasis
    G. David Roodman
    JCO 2005 23: 4821-4822 [Full Text]


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
T. Golombick, T. H. Diamond, V. Badmaev, A. Manoharan, and R. Ramakrishna
The Potential Role of Curcumin in Patients with Monoclonal Gammopathy of Undefined Significance--Its Effect on Paraproteinemia and the Urinary N-Telopeptide of Type I Collagen Bone Turnover Marker
Clin. Cancer Res., September 15, 2009; 15(18): 5917 - 5922.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al.
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
Ann. Onc., August 1, 2009; 20(8): 1303 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. J. Armstrong and P. G. Febbo
Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature
Oncologist, August 1, 2009; 14(8): 816 - 827.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Fulciniti, P. Tassone, T. Hideshima, S. Vallet, P. Nanjappa, S. A. Ettenberg, Z. Shen, N. Patel, Y.-t. Tai, D. Chauhan, et al.
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Blood, July 9, 2009; 114(2): 371 - 379.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
V. Guarneri and P. Conte
Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy
Oncologist, July 1, 2009; 14(7): 645 - 656.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Morris, N. Pandit-Taskar, J. Carrasquillo, C. R. Divgi, S. Slovin, W. K. Kelly, D. Rathkopf, G. A. Gignac, D. Solit, L. Schwartz, et al.
Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer
J. Clin. Oncol., May 20, 2009; 27(15): 2436 - 2442.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Fizazi, A. Lipton, X. Mariette, J.-J. Body, Y. Rahim, J. R. Gralow, G. Gao, L. Wu, W. Sohn, and S. Jun
Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
J. Clin. Oncol., April 1, 2009; 27(10): 1564 - 1571.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Vignot and D. Khayat
A Step in the Journey of Denosumab From Bone-Targeted Therapy to Seed- and Soil-Targeted Therapy
J. Clin. Oncol., April 1, 2009; 27(10): 1534 - 1536.
[Full Text] [PDF]

Home page
 The OncologistHome page
T. Van den Wyngaert, M. T. Huizing, E. Fossion, and J. B. Vermorken
Bisphosphonates in Oncology: Rising Stars or Fallen Heroes
Oncologist, February 1, 2009; 14(2): 181 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Cleveland Clinic Journal of MedicineHome page
F. R. SINGER and D. R. EYRE
Using biochemical markers of bone turnover in clinical practice
Cleveland Clinic Journal of Medicine, October 1, 2008; 75(10): 739 - 750.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-W. Qiang, J. D. Shaughnessy Jr, and S. Yaccoby
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth
Blood, July 15, 2008; 112(2): 374 - 382.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. E. Miller, M. Roudier, J. Jones, A. Armstrong, J. Canon, and W. C. Dougall
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis
Mol. Cancer Ther., July 1, 2008; 7(7): 2160 - 2169.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-H. Lin, Y.-C. Lee, M. B. Choueiri, S. Wen, P. Mathew, X. Ye, K.-A. Do, N. M. Navone, J. Kim, S.-M. Tu, et al.
Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer
Clin. Cancer Res., June 15, 2008; 14(12): 3729 - 3736.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Raje, S.-B. Woo, K. Hande, J. T. Yap, P. G. Richardson, S. Vallet, N. Treister, T. Hideshima, N. Sheehy, S. Chhetri, et al.
Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw
Clin. Cancer Res., April 15, 2008; 14(8): 2387 - 2395.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. B. Dodson, N. S. Raje, P. A. Caruso, and A. E. Rosenberg
Case 9-2008 -- A 65-Year-Old Woman with a Nonhealing Ulcer of the Jaw
N. Engl. J. Med., March 20, 2008; 358(12): 1283 - 1291.
[Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M M Muresan, P Olivier, J Leclere, F Sirveaux, L Brunaud, M Klein, R Zarnegar, and G Weryha
Bone metastases from differentiated thyroid carcinoma
Endocr. Relat. Cancer, March 1, 2008; 15(1): 37 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al.
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
Ann. Onc., March 1, 2008; 19(3): 420 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Zheng, H. Zhou, J. R.K. Modzelewski, R. Kalak, J. M. Blair, M. J. Seibel, and C. R. Dunstan
Accelerated Bone Resorption, Due to Dietary Calcium Deficiency, Promotes Breast Cancer Tumor Growth in Bone
Cancer Res., October 1, 2007; 67(19): 9542 - 9548.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Lipton, G. G. Steger, J. Figueroa, C. Alvarado, P. Solal-Celigny, J.-J. Body, R. de Boer, R. Berardi, P. Gascon, K. S. Tonkin, et al.
Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases
J. Clin. Oncol., October 1, 2007; 25(28): 4431 - 4437.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
P. G.J. Fournier and T. A. Guise
BMP7: A New Bone Metastases Prevention?
Am. J. Pathol., September 1, 2007; 171(3): 739 - 743.
[Full Text] [PDF]

Home page
 The OncologistHome page
A. Lipton, R. J. Cook, P. Major, M. R. Smith, and R. E. Coleman
Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity
Oncologist, September 1, 2007; 12(9): 1035 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J-J Body, M Lichinitser, S Tjulandin, P Garnero, and B Bergstrom
Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases
Ann. Onc., July 1, 2007; 18(7): 1165 - 1171.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. A. Kyle, G. C. Yee, M. R. Somerfield, P. J. Flynn, S. Halabi, S. Jagannath, R. Z. Orlowski, D. G. Roodman, P. Twilde, and K. Anderson
American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma
J. Clin. Oncol., June 10, 2007; 25(17): 2464 - 2472.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
V. O. Lewis
What's New in Musculoskeletal Oncology
J. Bone Joint Surg. Am., June 1, 2007; 89(6): 1399 - 1407.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Johansen, K. Brasso, P. Iversen, B. Teisner, P. Garnero, P. A. Price, and I. J. Christensen
Changes of Biochemical Markers of Bone Turnover and YKL-40 Following Hormonal Treatment for Metastatic Prostate Cancer Are Related to Survival
Clin. Cancer Res., June 1, 2007; 13(11): 3244 - 3249.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Lu, Z. Cai, G. Xiao, E. T. Keller, A. Mizokami, Z. Yao, G. D. Roodman, and J. Zhang
Monocyte Chemotactic Protein-1 Mediates Prostate Cancer-Induced Bone Resorption
Cancer Res., April 15, 2007; 67(8): 3646 - 3653.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. A. Guise
Bone Loss and Fracture Risk Associated with Cancer Therapy
Oncologist, November 1, 2006; 11(10): 1121 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Clemons, G. Dranitsaris, W. S. Ooi, G. Yogendran, T. Sukovic, B. Y.L. Wong, S. Verma, K. I. Pritchard, M. Trudeau, and D. E.C. Cole
Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy
J. Clin. Oncol., October 20, 2006; 24(30): 4895 - 4900.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. A. Guise, K. S. Mohammad, G. Clines, E. G. Stebbins, D. H. Wong, L. S. Higgins, R. Vessella, E. Corey, S. Padalecki, L. Suva, et al.
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.
Clin. Cancer Res., October 15, 2006; 12(20): 6213s - 6216s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. E. Coleman
Clinical features of metastatic bone disease and risk of skeletal morbidity.
Clin. Cancer Res., October 15, 2006; 12(20): 6243s - 6249s.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
M. R. Smith
Bisphosphonates for Metastatic Bone Disease -- Too Much of a Good Thing?
IBMS BoneKEy, September 1, 2006; 3(9): 24 - 27.
[Full Text] [PDF]

Home page
 The OncologistHome page
D. Cameron, M. Fallon, and I. Diel
Ibandronate: Its Role in Metastatic Breast Cancer
Oncologist, September 1, 2006; 11(suppl_1): 27 - 33.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Cook, R. Coleman, J. Brown, A. Lipton, P. Major, Y. J. Hei, F. Saad, and M. R. Smith
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.
Clin. Cancer Res., June 1, 2006; 12(11): 3361 - 3367.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. Caraglia, D. Santini, M. Marra, B. Vincenzi, G. Tonini, and A. Budillon
Emerging anti-cancer molecular mechanisms of aminobisphosphonates.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 7 - 26.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Clemons, G. Dranitsaris, D. Cole, and M. C. Gainford
Too Much, Too Little, Too Late to Start Again? Assessing the Efficacy of Bisphosphonates in Patients with Bone Metastases from Breast Cancer.
Oncologist, January 1, 2006; 11(3): 227 - 233.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
A. Lipton, R. E. Coleman, P. Major, J. E. Brown, K.-A. Lee, M. Smith, F. Saad, Y. Chen, Y. Jiang, and R. Cook
Baseline N-Telopeptide Levels Correlate with Risk of Skeletal Morbidity in Patients with Multiple Myeloma during Zoledronic Acid Therapy.
Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 3456 - 3456.
[Abstract]

Home page
 JCOHome page
G. D. Roodman
High Bone Turnover Markers Predict Poor Outcome in Patients With Bone Metastasis
J. Clin. Oncol., August 1, 2005; 23(22): 4821 - 4822.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online